Findings

What do systematic reviews say?

1,741 questions · 1,821 findings · 207 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 297 · 16.3%GRADE not reported 191 · 10.5%Very low 333 · 18.3%Low 466 · 25.6%Moderate 414 · 22.7%High 120 · 6.6%

One week of AmBd + FLU vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.18 [0.88, 1.58]
1 study · 225 participants
Moderate

One week of AmBd + FLU vs two weeks of AmBd + 5FC

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.27 [0.94, 1.72]
1 study · 226 participants
Moderate

One week of AmBd + FLU vs two weeks of 5FC + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + FLU probably leads to higher mortality: 10 weeks compared with two weeks of 5FC + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.39 [1.07, 1.8]
1 study · 336 participants
Moderate

Two weeks of FLU vs two weeks of 5FC + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of FLU changes mortality: 10 weeks compared with two weeks of 5FC + FLU (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.46 [0.96, 2.23]
2 studies · 98 participants
Very low

Two weeks of L‐AmB vs two weeks of AmBd

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of L‐AmB changes mortality: 10 weeks compared with two weeks of AmBd (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.43 [0.04, 4.25]
1 study · 28 participants
Very low

Short‐course L‐AmB + FLU vs two weeks of L‐AmB + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Short‐course L‐AmB + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of L‐AmB + FLU (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.03 [0.47, 2.25]
1 study · 79 participants
Low

Two weeks of AmBd + 5FC + FLU vs two weeks of AmBd + 5FC

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + 5FC (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 2.81 [0.33, 24.16]
1 study · 31 participants
Very low

Two weeks of AmBd + 5FC + FLU vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + FLU (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.43 [0.13, 1.37]
1 study · 32 participants
Very low

Two weeks of AmBd + 5FC + FLU vs two weeks of AmBd

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1 [0.24, 4.23]
1 study · 32 participants
Very low

One week of AmBd + 5FC vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.58 [0.39, 0.86]
1 study · 227 participants
Moderate

One week of AmBd + 5FC + FLU vs one week of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC + FLU showed no clear difference in mortality: 10 weeks compared with one week of AmBd + FLU (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.86 [0.35, 2.1]
1 study · 40 participants
Low

Two weeks of AmBd + 5FC + IFNg vs two weeks of AmBd + 5FC

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + 5FC + IFNg showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.92 [0.48, 1.77]
1 study · 88 participants
Low

One week of AmBd + 5FC vs one week of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with one week of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.49 [0.34, 0.72]
1 study · 224 participants
Moderate

One week of AmBd + 5FC vs two weeks of 5FC + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of 5FC + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.68 [0.47, 0.99]
1 study · 338 participants
Moderate

Two weeks of 5FC + FLU vs two weeks of AmBd + 5FC

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of 5FC + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.92 [0.69, 1.23]
1 study · 340 participants
Moderate

Two weeks of 5FC + FLU vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of 5FC + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.85 [0.64, 1.13]
1 study · 339 participants
Moderate

Two weeks of AmBd + 5FC vs two weeks of AmBd

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of AmBd (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.66 [0.46, 0.95]
2 studies · 231 participants
Moderate

Two weeks of AmBd + FLU vs two weeks of AmBd

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.94 [0.55, 1.62]
3 studies · 371 participants
Low

Two weeks of AmBd + 5FC vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + 5FC showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.9 [0.69, 1.19]
4 studies · 538 participants
Low

Prosthetic mesh placement vs usual care

Overall incidence of parastomal hernia ( · individuals having a stoma formation

Prosthetic mesh placement may leads to lower overall incidence of parastomal hernia ( compared with standard treatment (low certainty).

1 finding from 1 review

Prosthetic mesh placement for the prevention of parastomal herniation 2018 · Cochrane Headline outcomes only
RR 0.53 [0.43, 0.66]
10 studies · 771 participants
Low